18F-FDG PET in the management of patients with anaplastic thyroid carcinoma

Thyroid

Volumn 18, Issue 7, 2008, Pages 713-719

  Bogsrud, Trond Velde ^a,b   Karantanis, Dimitrios ^a   Nathan, Mark A ^a   Mullan, Brian P ^a   Wiseman, Gregory A ^a   Kasperbauer, Jan L ^a   Reading, Carl C ^a   Hay, Ian D ^a   Lowe, Val J ^a  

^a MAYO CLINIC   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; ASPIRATION BIOPSY; BONE SCINTISCANNING; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DISTANT METASTASIS; ECHOGRAPHY; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MEDICAL RECORD; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; THYROID CARCINOMA; TREATMENT PLANNING; CARCINOMA; COLOR ULTRASOUND FLOWMETRY; METABOLISM; METHODOLOGY; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY; THYROID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 47549092154     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0350     Document Type: Article

References (19)

1. Ara C, Shaha AR 2006 Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment. Ann Surg Oncol 13:453-464.
2. Comett WR, Shama AK, Day TA, Richardson MS, Hoda RS, van Heerden JA, Femandes JK 2007 Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep 9:152-158.
3. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 48:221-226.
4. 18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85:1107-1113.
5. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss W, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498-505.
6. 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med 47:1260-1266.
7. Jadvar H, Fischman AJ 1999 Evaluation of rare tumors with [F-18]fluorodeoxyglucose positron emission tomography. Clin Positron Imaging 2:153-158.
8. Kresnik E, Gallowitsch HJ, Mikosch P, Stettner H, Igerc I, Gomez I, Kumnig G, Lind P 2003 Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 133:294-299.
9. Poppe K, Lahouette T, Everaert H, Bossuyt A, Velkeniers B 2004 The utility of multimodality imaging in anaplastic thyroid carcinoma. Thyroid 14:981-982.
10. Nguyen BD, Ram PC 2007 PET/CT Staging and posttherapeutic monitoring of anaplastic thyroid carcinoma. Clin Nucl Med 32:145-149.
11. Iagaru A, McDougall R 2007 F-18 FDG PET/CT demonstrating of an adrenal metastasis in a patient with anaplastic thyroid cancer. Clin Nucl Med 32:13-15.
12. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H 1997 Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24:1342-1348.
13. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, Roedel R, Wolff M, Wardelmann E, Biersack HJ, Jaeger U 2006 Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47:616-624.
14. Zoller M, Kohlfuerst S, Igere I, Kresnik E, Gallowitsch H-J, Gomez I, Lind P 2006 Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging 34:487-495.
15. - symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84:3228-3234.
16. Schönberger J, Rüschoff J, Grimm D, Marienhagen J, Rümmele P, Meyringer R, Kossmehl P, Hofstaedter F, Eilles C 2002 Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavourable prognosis: an immunohistochemical study. Thyroid 12:747-754.
17. Rohren EM, Turkington TG, Coleman RE 2004 Clinical application of PET in oncology. Radiology 231:305-332.
18. Nahas Z, Goldenberg D, Fakhry C, Ewertz M, Zeiger M, Ladenson PW, Wahl R, Tufano RP 2005 The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 115:237-243.
19. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME 2001 A tabulated summary of the FDG PET literature. J Nucl Med 42:No 5 (theme issue).